Table 3.
Ontario data scenario analyses
| BLC | WLC | Net | Difference* | |
|---|---|---|---|---|
| Without BLC-additional equipment | ||||
| Initial costs | $25 524 410 | $16 544 963 | $8 976 447 | |
| Followup costs | ||||
| No recurrence | $6 480 842 | $5 804 944 | $675 898 | |
| Recurrences | $8 016 845 | $13 513 376 | −$5 496 531 | |
| 5-year costs (total) | $40 022 097 | $35 863 283 | $4 158 814 | −$674 095 |
| Cost-difference/case | $1181 | −$191 | ||
| Recurrences | 1351 | 1689 | −338 | 0 |
| Without postoperative mitomycin | ||||
| Initial costs | $23 706 733 | $14 826 550 | $8 880 182 | |
| Followup costs | ||||
| No recurrence | $6 480 842 | $5 804 944 | $675 898 | |
| Recurrences | $7 519 289 | $12 874 972 | −$5 355 683 | |
| 5-year costs (total) | $37 706 864 | $33 506 466 | $4 200 398 | −$632 511 |
| Cost-difference/case | $1193 | −$179 | ||
| Recurrences | 1351 | 1689 | −338 | 0 |
| 20% improvement in progression | ||||
| Initial costs | $26 165 385 | $16 544 963 | $9 620 422 | |
| Followup costs | ||||
| No recurrence | $6 571 009 | $5 804 944 | $766 065 | |
| Recurrences | $8 049 965 | $13 513 376 | −$5 463 411 | |
| Progression | $9 901 680 | $12 164 226 | −$2 262 546 | |
| 5-year costs (total) | $50 688 039 | $48 027 509 | $2 660 529 | −$2 172 380 |
| Cost-difference/case | $755 | −$617 | ||
| Recurrences | 1351 | 1689 | −338 | 0 |
| 50% improvement in progression | ||||
| Initial costs | $26 165 385 | $16 544 963 | $9 620 422 | |
| Followup costs | ||||
| No recurrence | $6 706 259 | $5 804 944 | $901 316 | |
| Recurrences | $8 049 965 | $13 513 376 | −$5 463 411 | |
| Progression | $6 507 861 | $12 164 226 | −$5 656 365 | |
| 5-year costs (total) | $47 429 470 | $48 027 509 | −$598 039 | −$5 430 948 |
| Cost-difference/case | −$170 | −$1542 | ||
| Recurrences | 1351 | 1689 | −338 | 0 |
| Only CIS** (n=317)# | ||||
| Initial costs | $2 968 779 | $1 918 103 | $1 050 676 | |
| Followup costs | ||||
| No recurrence | $536 891 | $478 850 | $58 041 | |
| Recurrences | $852 863 | $1 476 374 | −$623 511 | |
| 5-year costs (total) | $4 358 233 | $3 873 327 | $484 327 | |
| Cost-difference/case | $1528 | $156 | ||
| Recurrences | 136 | 169 | −33 | |
| Only intermediate-/high-grade (n=3170)# | ||||
| Initial costs | $22 096 531 | $13 875 308 | $8 221 222 | |
| Followup costs | ||||
| No recurrence | $5 773 887 | $5 168 103 | $605 784 | |
| Recurrences | $6 997 063 | $11 949 972 | −$4 952 909 | |
| 5-year costs (total) | $34 867 481 | $30 993 383 | $3 874 098 | |
| Cost-difference/case | $1222 | −$150 | ||
| Recurrences | 1246 | 1560 | −314 | |
*
Compared to baseline;
**
assumption – CIS is 20% of high-risk disease;
#
adjusted for no perioperative mitomycin instillation.
BLC: blue light cystoscopy; CIS: carcinoma in situ; WLC: white light cystoscopy.